Myovant Sciences: Return On Capital Employed Insights
During Q4, Myovant Sciences (NYSE:MYOV) brought in sales totaling $24.61 million. However, earnings decreased 1.75%, resulting in a loss of $76.95 million. Myovant Sciences collected $1.38 million in revenue during Q3, but reported earnings showed a $78.32 million loss.
Myovant Sciences’ Relugolix Combo Tablet For Uterine Fibroids Scores EMA Backing For Approval
European Medicines Agency’s advisory committee issued a positive opinion recommending the approval of Myovant Sciences Ltd’s (NYSE: MYOV) Ryeqo (relugolix, estradiol, and…
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 10)
Myovant Sciences Q4 EPS $(0.89) Beats $(0.99) Estimate, Sales $24.60M Miss $24.63M Estimate
Myovant Sciences (NYSE:MYOV) reported quarterly losses of $(0.89) per share which beat the analyst consensus estimate of $(0.99) by 10.1 percent. This is a 21.92 percent decrease over losses of $(0.73) per share from the
Earnings Scheduled For May 11, 2021
Companies Reporting Before The Bell
• Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter.
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came under pressure following the U.S.
98 Biotechnology Stocks Moving In Wednesday’s Session
Gainers • Neurotrope, Inc. (NASDAQ:NTRP) stock increased by 131.7% to $3.36 during Wednesday’s regular session. • Genprex, Inc.…